Targeted Oncology

FDA Grants Breakthrough Designation for Bezuclastinib in GIST

The FDA has granted breakthrough therapy designation (BTD) for bezuclastinib in combination with sunitinib (Sutent) for the ...
Monthly Prescribing Reference

FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations

In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%. The Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy ® (sunvozertinib) for ...
MedPage Today

Novel TKI, Sunvozertinib, in Platinum-Pretreated NSCLC Patients With Exon 20 Insertion Mutations

Exon 20 insertion mutations in non-small cell lung cancers have been a therapeutic challenge, and thus new agents targeting exon 20 mutations are a welcome addition. The study by James Chih-Hsin Yang ...
Seeking Alpha

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (ORIC), a clinical stage oncology company focused on developing treatments that address ...
ascopubs.org

FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).

A phase 2 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer. This is an ASCO Meeting ...